Alpha Cognition (TSX-V:ACOG, OTCQB:ACOGF) CEO Michael McFadden joins Natalie Stoberman from the Proactive studio to discuss the company's latest financial growth from new funding and reduced expenses and how its been highlighted by a new listing on the Canadian Stock Exchange.
Alpha Cognition is a clinical stage biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.